207_Combined course Presentations
Conclusion (CMT in Stage III)
Current standard regimens remain Carbo-tax and Cis-etoposide
Testing of targeted agents in appropriate populations is long overdue – no clear indication to date
Promising immune-therapy approaches are under investigation
Prognostic and predictive factors are needed
Made with FlippingBook